PREVENTION OF GASTRODUODENOPATHY INDUCED BY THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE JOINTS WITH EUPATILINE
DOI:
https://doi.org/10.31082/1728-452X-2021-225-3-28-35Keywords:
cytoprotector, gastropathy, enteropathy, eupatiline, osteoarthritisAbstract
The most common side effects from the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) are gastrointestinal, however, proton pump inhibitors and misoprostol recommended for their prevention often cause undesirable reactions and disorders themselves, so it is important to use alternative antioxidants with cytoprotective action, for example, eupatiline.
Objective. To evaluate the degree of protection of the gastroduodenal mucosa with eupatiline (the active substance of the drug Norvela) and tolerability in patients with osteoarthritis of the knee joints taking naproxen.
Material and methods. The main (naproxen and eupatilin) and control (naproxen only) groups of 25 patients with osteoarthritis of the knee joints of the second stage, comparable in gender and age, underwent endoscopic examination twice (at the beginning of the follow-up and two weeks later), with the determination of a urease test. Informed consent was obtained from patients to participate in the study.
The main result of the study. It was found that the use of eupatiline at a daily dose of 180 mg for 14 days in patients with osteoarthritis of the knee joints, against the background of taking a non-selective NSAID – naproxen at a daily dose of 825 mg for 10 days, is not only effective (degree of protection 84%), but also a relatively safe method of preventing the development of NSAIDs-gastroduodenopathies and their complications.
Discussion. The obtained results of the study echo other foreign and Kazakh studies based on endoscopic and histological data in favor of the use of eupatiline with a gastroprotective purpose.
Conclusion. The drug Norvela effectively acts locally in the mucous membrane of the gastrointestinal tract, enhances its own protective factors, has a long-lasting anti-inflammatory effect, accelerates normal regeneration and restoration of the damaged mucous membrane, is well tolerated, non-toxic, which allows it to be recommended for wider use for cytogastroprotection during the course of short-and/or long-term NSAID therapy, in particular naproxen, in patients with osteoarthritis of the knee joints.
References
Tae Oh Young, Byong Kweon Ryu, Jun I. Ko et al. Protective Effect of DA-9601, an Extract of Artemisiae Herba, against Naproxen-induced Gastric Damage in Arthritic Rats. Arch. Pharm. Res. 1997;20(5):414–419
Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? // Archives of Internal Medicine. 1986 vol. 146, Р. 1075-1076
Nasonov EL. Nonsteroidal anti-inflammatory drugs: problems of treatment safety // Consilium Medicum = Consilium Medicum. 1999;1(5):13-18 (In Russ.)
Klinicheskii protokol diagnostiki i lecheniia NPVP-indutsirovannykh gastropatii, Odobren Obieedinennoi komissiei po kachestvu meditsinskikh uslug Ministerstva zdravookhraneniia Respubliki Kazakhstan ot «19» aprelia 2019 goda, Protokol №63 [Clinical protocol for the diagnosis and treatment of NSAID-induced gastropathies, Approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan dated April 19, 2019, Protocol No. 63]. Available from: https://online.zakon.kz/Document/?doc_id=39701487
Karateev AE, Nasonov EL, Ivashkin VT, et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 1):1–29 (In Russ.). doi: 10.14412/1995-4484-2018-1-29
Lanza F, Chan FК, Quigley E, et al. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am. J. Gastroenterol. 2009;104(3):728–738. doi: 10.1038/ajg.2009.115
Moore RA, Sheena Derry, Lee S. Simon et al. Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit–Risk. Pain Pract. 2014;14:378–395. doi. 10.1111/papr.12100
Park Jun Yeon, Dahae Lee, Hyuk-Jai Jang et al. Protective Effect of Artemisia asiatica Extract and Its Active Compound Eupatilin against Cisplatin-Induced Renal Damage. Evid. Based Complement. Altern. Med. 2015;15:483980. doi: 10.1155/2015/483980
Tkach SM, Onishchuk LA. Efficacy and safety of eupatiline in the prevention of NSAID-gastropathies. Gazeta «Novosti meditsiny i farmatsii» = The newspaper "News of Medicine and Pharmacy". 2017;15(634):27-31. (In Russ.)
Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. 1998;93(11):2037–2046. doi: 10.1111/j.1572-0241.1998.00588.x.
Tae Young Oh, Joon-Young Lee, In So Kweon, et al. Robotics Cytoprotective effects of eupatilin, a novel antioxidative flavone, in oxidative stress-induced gastric mucosal cell damage. Gastroenterology. 2003;124;Is.4(Suppl.1):A
Eun-Ju Choi, Hyun-Mee Oh, Bo-Ra Na, et al. Eupatilin protects gastric epithelial cells from oxidative damage and down-regulates genes responsible for the cellular oxidative stress. Pharm Res. 2008;25(6):1355-64. doi: 10.1007/s11095-008-9531-5
Huh К., Kwon Т.Н., Shin U.S. et al. Inhibitory effects of DA-9601 on ethanol-induced gastrohemorrhagic lesions and gastric xanthine oxidase activity in rats. J. Ethnopharmacol. 2003;88(2–3):269–73. doi: 10.1016/s0378-8741(03)00235-6
Ko SH, Yoo DY, Kim YJ, et al. A mechanism for the action of the compound DA-6034 on NF-κB pathway activation in Helicobacter pylori-infected gastric epithelial cells. Scand J. Immunol. 2011;74(3):253–263. doi: 10.1111/j.1365-3083.2011.02577.x.
Lee JS, Kim HS, Hahm KB. Inhibitory effects of 7-carboxymethyloxy-3′,4′,5-trimethoxyflavone (DA-6034) on Helicobacter pylori-induced NF-kappa B activation and iNOS expression in AGS cells. Ann. NY Acad. Sci. 2007;1095:527–535. doi: 10.1196/annals.1397.057
Byeong Bae Park, Jin sun Yoon, Eun shil Kim et al. Inhibitory effects of eupatilin on tumor invasion of human gastric cancer MKN-1 cell. Tumor. Biol. 2013;34:875–885
Tae Young Oh. Chang Yell Shin, Yong Sung Sohn et al. Therapeutic effect of DA-9601 on chronic reflux gastritis induced by sodium taurocholate in rats. World J Gastroenterol. 2005;11(47):7430–7435. doi: 10.3748/wjg.v11.i47.7430
Dong Shin Kwak, Oh Young Lee, Kang Nyeong Lee, et al. Tu 1246 The effect of eupatillin on indomethacin induced small intestinal injury and intestinal permeability. Gastroenterology. 2014;146(50):S-794. doi: 10.1016/S0016-5085(14)62866-3
Eun-Ju Choi, Soyoung Lee, Jeong-Ryong Chae et al. Eupatilin inhibits lipopolysaccharide–induced expression of inflammatory mediators in macrophages. Life Sci. 2011;88(25–26):1121–6. doi: 10.1016/j.lfs.2011.04.011
Adamenko AI. Silivonchik NN. Stillen in the prevention of gastrointestinal tract lesions associated with the use of nonsteroidal anti-inflammatory drugs and aspirin: recommendations for practitioners. Meditsinskie novosti = Medical news. 2016;3:2-8. (In Russ.)
Sang Yong Seol, Myung Hwan Kim, Jong Sun Ryu et al. DA-9601 for erosive gastritis: Results of a double-blind placebo controlled phase III clinical trial. World J Gastroenterol. 2004;10(16):2379–2382
Ishimori A, Yamagata S, Taima T. Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study. Arzneimittelforschung. 1979;29(10):1625–1632
Kang Nyeong Lee, Oh Young Lee, Myung-Gyu Choi et al. Prevention of NSAID-Associated Gastroduodenal Injury in Healthy Volunteers-A Randomized, Double-Blind, Multicenter Study Comparing DA-9601 with Misoprostol. J Korean Med. Sci. 2011;26:1074–1080
Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs – nice or necessary? Rev. Gastroenterol. Disord. 2004;4(Suppl. 4): S33–S41
Oh Young Lee, Dae-Hwan Kang, Dong Ho Lee, et al. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch. Pharm. Res. 2014;37(10):1308–1316. doi: 10.1007/s12272-014-0408-3
Marakhovsky YuKh, Marakhovsky KYu. Achievements in cytoprotection of the gastric mucosa (2016): analytical review. Lechebnoe delo = Medical business. 2016:3(49):47-55. (In Russ.)
Jeong JH, Moon SJ, Jhun JY, Yang EJ, Cho ML, Min JK. Eupatilin Exerts Antinociceptive and Chondroprotective Properties in a Rat Model of Osteoarthritis by Downregulating Oxidative Damage and Catabolic Activity in Chondrocytes. PLoS ONE. 2015;10(6):e0130882. doi:10.1371/journal.pone.0130882
Seung-Bum Ryoo, Heung-Kwon Oh, Sung AYu, et al. The Effect of Eupatilin (Stillen®) on Motility of Human Lower Gastrointestinal Tracts. Korean J Physiol Pharmacol. 2014;18:383–390
Kaibullayeva DA, Shumkov YuP, Khabizhanova AS, Ismailov SB, Takhaev ZV, Alieva LN, Dushpanova AT, Ibraeva ET. Experience of using the drug "Norvela" in the treatment of NSAID-induced gastropathy. Farmatsiia Kazakhstana = Pharmacy of Kazakhstan. 2016;6:27-32. (In Russ.)
